Tg Therapeutics: 15-Min Chart Shows KDJ Golden Cross, Bullish Marubozu Pattern

Tg Therapeutics's 15-minute chart has recently exhibited a notable trend reversal, as indicated by the KDJ Golden Cross and Bullish Marubozu patterns at 09/30/2025 14:00. This suggests that the momentum of the stock price is shifting towards an upward trajectory, with a potential for further increase. As the buyers have taken control of the market, a continued bullish momentum is likely to prevail.

Tg Therapeutics, Inc. (TGTX) has recently exhibited a notable trend reversal in its stock price, as indicated by the KDJ Golden Cross and Bullish Marubozu patterns on its 15-minute chart as of September 30, 2025, at 14:00. This suggests a shift in momentum towards an upward trajectory, with potential for further increase. The presence of these patterns indicates that buyers have taken control of the market, signaling a continued bullish momentum.

These chart patterns, along with the company's recent positive announcements, could be influencing investor sentiment. Tg Therapeutics announced updated data presentations at the 2025 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting, including new six-year data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS) Tg Therapeutics, Inc. Announces Updated Data Presentation Including New Six-Year Data from the Ultimate I & Ii Phase 3 Trials Evaluating Briumvi®?^[1]. The consistency of outcomes in clinical trials compared with emerging data from observational studies strongly supports the use of ublituximab in clinical practice.

Moreover, the company reported no association between decreased immunoglobulin levels and risk of serious infections after 6 years of treatment. Consolidating Day 1 and Day 15 BRIUMVI infusions into a single 600 mg dose on Day 1 was well-tolerated across various infusion durations, with the 4-hour infusion associated with the lowest infusion-related reaction (IRR) rate. This is currently being evaluated in a double-blinded, randomized, label-enabling trial design compared to standard dosing.

Investors should closely monitor Tg Therapeutics' stock performance and the ongoing clinical trials to gauge the potential impact on the company's valuation. The recent trend reversal and positive clinical data suggest that Tg Therapeutics may be poised for further growth.